278 related articles for article (PubMed ID: 12124341)
1. The fragile histidine triad/common chromosome fragile site 3B locus and repair-deficient cancers.
Turner BC; Ottey M; Zimonjic DB; Potoczek M; Hauck WW; Pequignot E; Keck-Waggoner CL; Sevignani C; Aldaz CM; McCue PA; Palazzo J; Huebner K; Popescu NC
Cancer Res; 2002 Jul; 62(14):4054-60. PubMed ID: 12124341
[TBL] [Abstract][Full Text] [Related]
2. Identification of unstable sequences within the common fragile site at 3p14.2: implications for the mechanism of deletions within fragile histidine triad gene/common fragile site at 3p14.2 in tumors.
Corbin S; Neilly ME; Espinosa R; Davis EM; McKeithan TW; Le Beau MM
Cancer Res; 2002 Jun; 62(12):3477-84. PubMed ID: 12067991
[TBL] [Abstract][Full Text] [Related]
3. Reduced Fhit expression in sporadic and BRCA2-linked breast carcinomas.
Ingvarsson S; Agnarsson BA; Sigbjornsdottir BI; Kononen J; Kallioniemi OP; Barkardottir RB; Kovatich AJ; Schwarting R; Hauck WW; Huebner K; McCue PA
Cancer Res; 1999 Jun; 59(11):2682-9. PubMed ID: 10363992
[TBL] [Abstract][Full Text] [Related]
4. The Fragile Histidine Triad gene and breast cancer.
Yang Q; Yoshimura G; Sakurai T; Kakudo K
Med Sci Monit; 2002 Jul; 8(7):RA140-4. PubMed ID: 12118213
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands.
Ahmadian M; Wistuba II; Fong KM; Behrens C; Kodagoda DR; Saboorian MH; Shay J; Tomlinson GE; Blum J; Minna JD; Gazdar AF
Cancer Res; 1997 Sep; 57(17):3664-8. PubMed ID: 9288768
[TBL] [Abstract][Full Text] [Related]
6. Positions of chromosome 3p14.2 fragile sites (FRA3B) within the FHIT gene.
Zimonjic DB; Druck T; Ohta M; Kastury K; Croce CM; Popescu NC; Huebner K
Cancer Res; 1997 Mar; 57(6):1166-70. PubMed ID: 9067288
[TBL] [Abstract][Full Text] [Related]
7. Loss of Msh2 is not associated with FHIT deletion in breast carcinomas.
Yang Q; Nakamura Y; Nakamura M; Yoshimura G; Suzuma T; Umemura T; Mori I; Sakurai T; Kakudo K
Anticancer Res; 2002; 22(5):2591-5. PubMed ID: 12529969
[TBL] [Abstract][Full Text] [Related]
8. Deletions of BRCA1/2 and p53 R248W gain-of-function mutation suggest impaired homologous recombination repair in fragile histidine triad-negative sebaceous gland carcinomas.
Becker K; Goldberg M; Helmbold P; Holbach LM; Loeffler KU; Ballhausen WG
Br J Dermatol; 2008 Dec; 159(6):1282-9. PubMed ID: 18717684
[TBL] [Abstract][Full Text] [Related]
9. Induction of the common fragile site FRA3B does not affect FHIT expression.
Michael D; Rajewsky MF
Oncogene; 2001 Mar; 20(14):1798-801. PubMed ID: 11313927
[TBL] [Abstract][Full Text] [Related]
10. The murine Fhit gene is highly similar to its human orthologue and maps to a common fragile site region.
Glover TW; Hoge AW; Miller DE; Ascara-Wilke JE; Adam AN; Dagenais SL; Wilke CM; Dierick HA; Beer DG
Cancer Res; 1998 Aug; 58(15):3409-14. PubMed ID: 9699673
[TBL] [Abstract][Full Text] [Related]
11. Absence of Msh2 protein expression is associated with alteration in the FHIT locus and Fhit protein expression in colorectal carcinoma.
Mori M; Mimori K; Masuda T; Yoshinaga K; Yamashita K; Matsuyama A; Inoue H
Cancer Res; 2001 Oct; 61(20):7379-82. PubMed ID: 11606365
[TBL] [Abstract][Full Text] [Related]
12. Components of DNA damage checkpoint pathway regulate UV exposure-dependent alterations of gene expression of FHIT and WWOX at chromosome fragile sites.
Ishii H; Mimori K; Inageta T; Murakumo Y; Vecchione A; Mori M; Furukawa Y
Mol Cancer Res; 2005 Mar; 3(3):130-8. PubMed ID: 15798093
[TBL] [Abstract][Full Text] [Related]
13. [Abnormal expression of fragile histidine triad (FHIT) and Mut S homolog 2 (MSH2) proteins in human sporadic colorectal carcinoma and their clinical significance].
Yao CC; Lin CY; Hu MB
Ai Zheng; 2004 Mar; 23(3):310-6. PubMed ID: 15025965
[TBL] [Abstract][Full Text] [Related]
14. FHIT alterations in breast cancer.
Ingvarsson S
Semin Cancer Biol; 2001 Oct; 11(5):361-6. PubMed ID: 11562178
[TBL] [Abstract][Full Text] [Related]
15. The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma.
Guler G; Uner A; Guler N; Han SY; Iliopoulos D; Hauck WW; McCue P; Huebner K
Cancer; 2004 Apr; 100(8):1605-14. PubMed ID: 15073846
[TBL] [Abstract][Full Text] [Related]
16. Comparative genomic mapping of the bovine Fragile Histidine Triad (FHIT) tumour suppressor gene: characterization of a 2 Mb BAC contig covering the locus, complete annotation of the gene, analysis of cDNA and of physiological expression profiles.
Uboldi C; Guidi E; Roperto S; Russo V; Roperto F; Di Meo GP; Iannuzzi L; Floriot S; Boussaha M; Eggen A; Ferretti L
BMC Genomics; 2006 May; 7():123. PubMed ID: 16719907
[TBL] [Abstract][Full Text] [Related]
17. Two-hit inactivation of FHIT by loss of heterozygosity and hypermethylation in breast cancer.
Yang Q; Nakamura M; Nakamura Y; Yoshimura G; Suzuma T; Umemura T; Shimizu Y; Mori I; Sakurai T; Kakudo K
Clin Cancer Res; 2002 Sep; 8(9):2890-3. PubMed ID: 12231533
[TBL] [Abstract][Full Text] [Related]
18. [Loss of fragile histidine triad expression and metastasis in breast cancer].
Zhao P; Li XY; Chen LZ
Ai Zheng; 2002 Jun; 21(6):668-70. PubMed ID: 12452072
[TBL] [Abstract][Full Text] [Related]
19. Inactivation of the human fragile histidine triad gene at 3p14.2 in monochromosomal human/mouse microcell hybrid-derived severe combined immunodeficient mouse tumors.
Kholodnyuk ID; Szeles A; Yang Y; Klein G; Imreh S
Cancer Res; 2000 Dec; 60(24):7119-25. PubMed ID: 11156420
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic silencing contributes to frequent loss of the fragile histidine triad tumour suppressor in basal cell carcinomas.
Goldberg M; Rummelt C; Laerm A; Helmbold P; Holbach LM; Ballhausen WG
Br J Dermatol; 2006 Dec; 155(6):1154-8. PubMed ID: 17107382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
